Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

Biogen, AbbVie multiple sclerosis drug wins EU green light

Written by: | no-reply@reuters.com | Dated: Friday, April 29th, 2016

 

The European Medicines Agency said on Friday its experts had endorsed Zinbryta, or daclizumab, for the treatment of relapsing forms of multiple sclerosis (MS), adding a new option to a range of modern MS therapies.

The positive opinion will now be referred to the European Commission, which normally grants marketing authorizations for medicines recommended by the agency within a couple of months.

The self-administered, under-the-skin injection is also currently being reviewed by regulators in the United States, Switzerland, Canada and Australia.

 

(Reporting by Ben Hirschler; Editing by Mark Potter)

Source: Reuters Health

http://www.reuters.com/article/us-biogen-abbvie-europe-idUSKCN0XQ1AC

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

June 2018 Focus: Biotech, Payer Access, DTC and more!

Subscribe

Ad Right Bottom

Main Navigation